On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door ...

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...